Traws Pharma, Inc. (TRAW) Reports Q3 Results and Clinical Program Updates
Traws Pharma reported financial results for the quarter ended September 30, 2026, and provided program updates. The release does not state financial figures; final Phase 2a results support further evaluation of ratutrelvir, and the company expects to resubmit TXM's updated toxicology package in Q4…